Criteria for inclusion: a) Program is in phase-3 or beyond and is non-partnered. b) Company does not have enough cash to bring the product to market.
Edits: Removed – MDVN (MDV-3100 partnered with Astellas)
Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- ARNA Lorcaserin Phase 3 Obesity BPAX Libigel Phase 3 ~2010 Submit Adequate Safety CHTP Droxidopa Pivotal Phase III Orthostatic hypotension. Results expected 02/09. CRGB Abiraterone Phase 3 Prostate cancer DYAX DX-88 for HAE BLA filed 9/24/08 (CABG indication partnered w CBST) GNVC TNFerade Pivotal Phase III Pancreatic cancer JAV Dyloject Phase III Approved in UK. Post operative Pain (injectable) JAV Ketamine Phase III Acute moderate-to-severe pain (intranasal) OREX Contrave Phase 3 Obesity OXGN Zybrestat Phase 3 Anaplastic thyroid cancer Pharming Rhucin Pre-BLA Rejected in EU Protalix prGCD Phase III Gaucher's disease. Not enough cash for a commercial infrastructure RPRX Proellex Phase 3 Uterine fibroids SVNT Puricase BLA filed Treatment refratory gout
Procedure for Updating Table
1. Copy the text in this post into a word processor.
2. Using a monospace font (e.g. Courier) to facilitate tabular alignment, make your additions and modifications, inserting them in the table in alphabetical order. NOTE: use spaces rather than tab characters.
3. Add a brief note in the “Edits:” line atop the table to describe your changes.
4. Insert the iHub formatting directives: Put [ pre ] at the beginning of the table without the surrounding spaces, and put [ /pre ] at the end of the table without the surrounding spaces.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.